Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management
Open Access
- 5 April 2024
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 31 (4) , 2076-2091
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous class of cancers, predominately occurring in the gastroenteropancreatic system, which pose a growing health concern with a significant rise in incidence over the past four decades. Emerging from neuroendocrine cells, these tumors often elicit paraneoplastic syndromes such as carcinoid syndrome, which can manifest as a constellation of symptoms significantly impacting patients’ quality of life. The prognosis of NETs is influenced by their tendency for metastasis, especially in cases involving the liver, where the estimated 5-year survival is between 20 and 40%. Although surgical resection remains the preferred curative option, challenges emerge in cases of neuroendocrine tumors with liver metastasis (NELM) with multifocal lobar involvement, and many patients may not meet the criteria for surgery. Thus, minimally invasive and non-surgical treatments, such as locoregional therapies, have surfaced. Overall, these approaches aim to prioritize symptom relief and aid in overall tumor control. This review examines locoregional therapies, encompassing catheter-driven procedures, ablative techniques, and radioembolization therapies. These interventions play a pivotal role in enhancing progression-free survival and managing hormonal symptoms, contributing to the dynamic landscape of evolving NELM treatment. This review meticulously explores each modality, presenting the current state of the literature on their utilization and efficacy in addressing NELM.Keywords
This publication has 138 references indexed in Scilit:
- Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United StatesJAMA Network Open, 2021
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastasesCancer, 2018
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- The epidemiology of metastases in neuroendocrine tumorsInternational Journal of Cancer, 2016
- The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE)European Journal of Nuclear Medicine and Molecular Imaging, 2014
- 18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their typeEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic diseaseBritish Journal of Surgery, 2009
- Cryotherapy for neuroendocrine liver metastasesSeminars in Surgical Oncology, 1998
- Neuroendocrine metastases of the liverWorld Journal of Surgery, 1995